Neutrophil-activating therapy for the treatment of cancer
Ian L. Linde, Edgar G. Engleman(Stanford University)
Cited by 196
Related Papers
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
|Annual Review of Pathology Mechanisms of Disease|2020|2.2k
B-1a Lymphocytes Attenuate Insulin Resistance
|Diabetes|2014|109
Akt and SHP-1 are DC-intrinsic checkpoints for tumor immunity
|JCI Insight|2016|27